Antoni Ribas, MD, PhD
The past decade of drug discovery has brought a dramatic expansion in the number of new therapies to treat patients with advanced or metastatic melanoma in 2 modalities: checkpoint blockade immunotherapies and molecularly targeted drugs. In both areas, these therapeutic categories have grown from single-agent regimens into combination strategies.
Figure. Merging Strategies in Melanoma Therapy1
The triplet strategies combine a monoclonal antibody targeting either PD-1 or PD-L1 with drugs that inhibit BRAF and MEK kinases, which are key components of the protein signaling pathway within the melanoma cell.
Table. Selected Melanoma Trials Exploring 3-Drug Combinations
“Three phase I trials attest to the overall safety of combined full-dose therapy with a BRAF and a MEK inhibitor with anti–PD-1/PD-L1 and provide early encouraging evidence of combined efficacy,” Ribas said. “There are toxicities, but they are usually responsive to stopping the targeted therapies for a little bit of time and then restarting.”
... to read the full story